PDC3 Antibody

What is PDCL3 and why is it important in research?

PDCL3 (phosducin-like 3) is a protein involved in cell cycle regulation and DNA repair processes. It plays a crucial role in maintaining genomic stability and ensuring proper cell division . Research has identified PDCL3 as a novel oncogene and potential biomarker in multiple cancers, particularly in hepatocellular carcinoma and glioma . Its involvement in DNA damage response pathways and cell cycle control makes it a promising target for studying diseases where disruptions in these processes occur, such as cancer .

What are the common applications for PDCL3 antibodies in research?

PDCL3 antibodies are utilized in various research applications, primarily:

These applications enable researchers to study PDCL3 expression, localization, and interactions in various experimental contexts .

How should I optimize PDCL3 antibody dilutions for Western blot experiments?

When optimizing PDCL3 antibody dilutions for Western blot, a systematic approach is recommended:

• Start with a moderate dilution (1:1000-1:2000) based on manufacturer recommendations

• Perform a gradient dilution experiment if signal strength is suboptimal

• Consider the following technical parameters:

  • Use 3-5% BSA in TBST for blocking and antibody dilution to reduce background

  • Incubate with primary antibody at 4°C overnight for optimal binding

  • Expected band size is approximately 28 kDa (calculated), though observed bands typically appear at 35-37 kDa due to post-translational modifications

  • Include positive control lysates such as A2780, MCF-7, or U251 cells, which are known to express PDCL3

Research has shown that using protein G purification methods for PDCL3 antibodies provides >95% purity and optimal specificity for Western blot applications .

What controls should I include when using PDCL3 antibodies for immunofluorescence studies?

For rigorous immunofluorescence experiments with PDCL3 antibodies:

• Positive controls: Include cell lines with validated PDCL3 expression (HepG2, MCF-7, HeLa cells)

• Negative controls:

  • Omit primary antibody incubation

  • Use non-specific IgG antibodies of the same isotype and concentration

  • When possible, include PDCL3 knockdown cells or tissues

• Validation approaches:

  • Perform peptide competition assays to confirm binding specificity

  • Correlate IF results with Western blot data from the same samples

  • Compare staining patterns with published subcellular localization data

  • Consider dual staining with a different PDCL3 antibody recognizing a distinct epitope

Research demonstrates that PDCL3 typically shows cytoplasmic and perinuclear localization patterns in immunofluorescence experiments .

How does PDCL3 expression correlate with clinical outcomes in cancer research?

Multiple studies have demonstrated significant correlations between PDCL3 expression and clinical outcomes:

When interpreting PDCL3 expression data in your research, consider:

• The specific cancer type and subtypes being studied

• The methodology used for expression analysis (IHC, WB, RT-PCR)

• Correlation with other established biomarkers

• Validation across multiple cohorts and databases

How can I differentiate between normal and pathological PDCL3 expression in tissue samples?

Distinguishing normal from pathological PDCL3 expression requires:

• Quantitative assessment:

  • Use digital image analysis software to quantify staining intensity

  • Compare expression levels in tumor vs. adjacent normal tissue within the same sample

  • Establish expression thresholds based on literature or your own cohort analysis

• Morphological assessment:

  • Normal tissues show moderate, even staining patterns

  • Pathological expression often displays:

    • Increased staining intensity

    • Altered subcellular localization

    • Heterogeneous expression patterns within the tissue

• Clinical correlation:

  • Higher PDCL3 expression correlates with:

    • Higher WHO grades in glioma

    • More advanced clinical and pathological stages in hepatocellular carcinoma

    • Poorer survival outcomes across multiple cancer types

Research has shown that IHC scoring of PDCL3 can effectively distinguish between WHO grade II, III, and IV gliomas, with significantly higher expression in higher-grade tumors .

How does PDCL3 interact with immune cell infiltration in the tumor microenvironment?

PDCL3 has been shown to significantly influence immune cell infiltration in the tumor microenvironment:

• Macrophage infiltration:

  • In hepatocellular carcinoma, PDCL3 expression shows a negative correlation with macrophage infiltration (Rho = −0.481, p = 2.13e−21)

  • High PDCL3 expression combined with decreased macrophage infiltration indicates poor prognosis

• Multiple immune cell correlations:

  • In glioma, PDCL3 expression positively correlates with infiltration of:

    • M1 and M2 macrophages

    • CD4+ and CD8+ T cells

    • Regulatory T cells (Tregs)

    • Dendritic cells

• Immune checkpoint correlation:

  • PDCL3 expression positively correlates with multiple immune checkpoint genes, including:

    • CD276, CXCL10, PRF1, CXCL9, VEGFA, SLAMF7, CD70, BTN3A1, TNFRSF4, and IDO1

    • Important immune checkpoints like PD-1, PD-L1, CTLA4, LAG3, HAVCR2, CD276, and IDO1

These findings suggest that PDCL3 may play a critical role in tumor immunoregulation and could potentially influence response to immunotherapy .

What techniques can be used to study PDCL3 interactions with other proteins?

Several advanced techniques can be employed to study PDCL3 protein-protein interactions:

• Immunoprecipitation-Mass Spectrometry (IP-MS):

  • Demonstrated in studies where myc-tagged PDCL3 was expressed in U251 cells, lysed in IP buffer, and precipitated using anti-myc antibody

  • Protocol details: Use of 1% NP-40, 50 mM NaF, 2 mM Na3VO4, 4 mM Na pyrophosphate and protease inhibitors in lysis buffer

• Co-immunoprecipitation (Co-IP):

  • Effective for confirming direct interactions, as demonstrated in studies of PDCL3 interaction with VEGFR-2

  • Both forward (immunoprecipitate with anti-VEGFR-2 antibody and blot for PDCL3) and reverse (immunoprecipitate with anti-PDCL3 and blot for interacting protein) approaches should be used for validation

• Proximity Ligation Assay (PLA):

  • Enables visualization of protein interactions in situ within cells

  • Particularly useful for studying interactions that may be transient or context-dependent

• Protein-fragment Complementation Assays:

  • Split GFP or luciferase complementation assays can assess interactions in living cells

• FRET/BRET Analyses:

  • These energy transfer techniques provide spatial information about protein interactions in living cells

Research has demonstrated that combining multiple approaches provides the most robust evidence for protein-protein interactions involving PDCL3 .

Why might I observe PDCL3 at different molecular weights in Western blot experiments?

The discrepancy between calculated (28 kDa) and observed (35-37 kDa) molecular weights of PDCL3 in Western blot analysis can be attributed to several factors:

• Post-translational modifications:

  • Phosphorylation sites have been identified on PDCL3

  • Glycosylation may affect mobility on SDS-PAGE

  • Ubiquitination can alter apparent molecular weight

• Technical considerations:

  • Different percentage gels (10% vs. 12%) can affect protein migration

  • Running conditions (voltage, buffer composition) influence apparent molecular weight

  • Sample preparation methods (reducing agents, denaturation temperature)

• Antibody specificity:

  • Different antibodies targeting different epitopes may recognize different isoforms or modified forms of PDCL3

  • Antibody cross-reactivity with related proteins should be considered

Multiple studies have consistently reported observing PDCL3 at approximately 35-37 kDa despite its calculated molecular weight of 28 kDa , suggesting that post-translational modifications play a significant role in its apparent molecular weight on Western blots.

How can I improve signal-to-noise ratio when using PDCL3 antibodies in immunohistochemistry?

To optimize signal-to-noise ratio in IHC experiments with PDCL3 antibodies:

• Antigen retrieval optimization:

  • Compare heat-induced (citrate buffer, pH 6.0) vs. enzymatic retrieval methods

  • Optimize retrieval time (10-30 minutes) based on tissue type and fixation

• Blocking improvements:

  • Extend blocking time (1-2 hours) with 5-10% normal serum matching the secondary antibody host

  • Add 0.1-0.3% Triton X-100 to reduce background in some tissues

  • Consider dual blocking with both serum and 1-5% BSA

• Antibody concentration and incubation:

  • Perform a dilution series (1:50 to 1:500) to determine optimal concentration

  • Extend primary antibody incubation to overnight at 4°C

  • Use antibody diluent containing 0.05-0.1% Tween-20 to reduce non-specific binding

• Detection system selection:

  • Polymer-based detection systems often provide superior signal-to-noise compared to ABC methods

  • Tyramide signal amplification can enhance sensitivity for low-abundance targets

• Technical considerations:

  • Use humid chambers to prevent section drying

  • Include PBS-T (0.1% Tween-20) in wash steps

  • Consider automated staining platforms for consistency

Research has shown that optimizing antigen retrieval and blocking steps are particularly important for achieving specific PDCL3 staining in tissues with high endogenous peroxidase activity .

How can PDCL3 knockdown/overexpression be used to study its function in cancer cells?

PDCL3 functional studies using knockdown and overexpression approaches have provided valuable insights:

• Knockdown approaches:

  • RNA interference (shRNA/siRNA) has been effectively used in HepG2 and Huh-7 cell lines

  • CRISPR-Cas9 gene editing can create stable PDCL3 knockout cell lines

  • Validation of knockdown efficiency should be performed at both mRNA (qRT-PCR) and protein (Western blot) levels

• Overexpression strategies:

  • Lentiviral vectors expressing myc-tagged PDCL3 have been successfully used in 97-H cells

  • Inducible expression systems allow temporal control of PDCL3 expression

  • Tagged constructs (myc, FLAG, GFP) facilitate detection and purification

• Functional assays following manipulation:

  • Proliferation: CCK-8 assay shows decreased proliferation in PDCL3 knockdown cells and increased proliferation in PDCL3 overexpressing cells

  • Migration/Invasion: Transwell and scratch assays reveal PDCL3 promotes these processes

  • Colony formation: PDCL3 enhances colony formation capacity

• Transcriptome analysis:

  • RNA sequencing of PDCL3 knockdown cells has identified 327 differentially expressed genes

  • Gene Ontology and KEGG pathway enrichment analyses reveal PDCL3's involvement in critical biological processes

Studies have demonstrated that PDCL3 knockdown significantly inhibits proliferation, migration, and invasion of liver cancer cell lines, while overexpression enhances these malignant characteristics .

What are the methodological considerations for studying PDCL3's role in immune modulation?

When investigating PDCL3's immunomodulatory functions:

• Selection of appropriate model systems:

  • Human cancer cell lines with varying PDCL3 expression

  • Co-culture systems with immune cells (macrophages, T cells)

  • Patient-derived xenografts or organoids preserving tumor immune microenvironment

  • Syngeneic mouse models for in vivo immune studies

• Immune cell infiltration analysis:

  • Flow cytometry panels to quantify immune cell subpopulations

  • Multiplex immunofluorescence to maintain spatial context

  • Single-cell RNA sequencing to identify cell populations and states

  • Computational algorithms for quantification (TIMER, quanTIseq, CIBERSORT)

• Functional immune assays:

  • T cell cytotoxicity assays against PDCL3-modulated cancer cells

  • Macrophage polarization analysis (M1/M2) in the presence of PDCL3-expressing cells

  • Cytokine/chemokine profiling using multiplexed assays

• Correlation with clinical data:

  • Integration of PDCL3 expression with immune infiltration data from patient cohorts

  • Association with response to immunotherapies (when available)

  • Correlation with immune checkpoint expression (PD-1, PD-L1, CTLA-4)

Research has shown that PDCL3 expression negatively correlates with macrophage infiltration in hepatocellular carcinoma, while showing positive correlations with various immune cell populations in glioma, highlighting the context-dependent nature of its immunomodulatory effects .

How might PDCL3 antibodies be utilized in targeted cancer therapy approaches?

PDCL3's potential as a therapeutic target is emerging based on several lines of evidence:

• Targeted antibody approaches:

  • Antibody-drug conjugates (ADCs) targeting PDCL3-expressing cells

  • Bispecific antibodies engaging PDCL3 and immune effector cells

  • Considerations for antibody development include:

    • Selection of high-affinity antibodies with optimal tumor penetration

    • Engineering for reduced immunogenicity

    • Optimization of drug-to-antibody ratio for ADCs

• Combination therapy potential:

  • PDCL3 knockdown sensitizes cancer cells to conventional therapies

  • Targeting PDCL3 in combination with immune checkpoint inhibitors

  • Potential synergy with anti-angiogenic therapies given PDCL3's interaction with VEGFR-2

• Precision medicine applications:

  • Patient stratification based on PDCL3 expression levels

  • Development of companion diagnostics for PDCL3-targeted therapies

  • Monitoring treatment response through PDCL3 expression changes

• Technical considerations:

  • Antibody specificity and cross-reactivity assessment

  • Biodistribution and pharmacokinetic profiles

  • Target-mediated drug disposition

While direct therapeutic applications are still emerging, given the critical role of PDCL3 in cancer cell proliferation, migration, and immune modulation, targeting PDCL3 represents a promising therapeutic strategy that warrants further investigation .

What methodological advances are improving the specificity and sensitivity of PDCL3 detection in complex biological samples?

Recent methodological advances enhancing PDCL3 detection include:

• Advanced antibody engineering:

  • Recombinant antibody technology improving batch-to-batch consistency

  • Single-domain antibodies offering improved tissue penetration

  • Site-specific conjugation methods for reporter molecules

• Multiplexed detection systems:

  • Multiplex immunofluorescence allowing simultaneous detection of PDCL3 and interacting partners

  • Mass cytometry (CyTOF) enabling detection of >40 parameters simultaneously

  • Digital spatial profiling combining protein and RNA detection in spatial context

• Signal amplification strategies:

  • Proximity extension assays for ultra-sensitive detection

  • Tyramide signal amplification enhancing conventional IHC sensitivity

  • Quantum dot conjugates providing improved signal-to-noise ratios

• Computational approaches:

  • Machine learning algorithms for automated image analysis of PDCL3 staining patterns

  • Data-driven image analysis to quantify subtle changes in localization and expression

  • Tite-Seq approach for measuring binding affinities in massively parallel fashion

These technological advances are enabling researchers to detect PDCL3 with greater sensitivity and specificity across diverse experimental contexts, from single-cell analysis to complex tissue environments, facilitating more nuanced understanding of its biological functions.